Business Context and Reporting Period
This Form 8-K Current Report was filed by GERON CORPORATION on March 25, 2026. The filing reports the election of two new directors to the Company's Board of Directors, effective immediately.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the expansion of the Board of Directors:
- Patricia S. Andrews was elected as a Class III director and appointed to the Audit Committee.
- Constantine Chinoporos was elected as a Class III director.
- Both directors serve terms expiring at the 2026 Annual Meeting of Stockholders.
Guidance, Outlook, and Management Commentary
The filing contains no financial guidance, outlook, or management commentary regarding business operations. It details the following governance and compensation arrangements:
- Compensation: New directors will receive cash and equity compensation in accordance with the Company's standard arrangements for non-employee directors, as described in the Schedule 14A proxy statement filed on April 8, 2025.
- Indemnification: The Company will enter into standard indemnification agreements with the new directors, potentially covering expenses, judgments, fines, and settlement amounts arising from their service.
- Background: Ms. Andrews brings extensive experience in oncology commercialization and board governance (Glenmark Pharmaceuticals, Oncolytics Biotech). Mr. Chinoporos brings significant experience in business development and corporate finance (Applied Therapeutics, Albireo Pharmaceuticals, Sanofi).
Investor Verification Checklist
- Verify the specific cash and equity compensation amounts for non-employee directors in the Schedule 14A proxy statement filed on April 8, 2025.
- Review the standard form of indemnification agreement (Exhibit 10.1 to the 2011 Form 10-K) to understand the scope of potential financial liabilities.
- Confirm the composition of the Audit Committee following Ms. Andrews' appointment.
- Check for any subsequent filings regarding the 2026 Annual Meeting of Stockholders where these directors' terms will expire.